Abbott Laboratories

$107.10

-0.00 (-0.00%) Today
1 Day1D

5 Days5D

1 Month1M

6 Months6M

YTDYTD

1 Year1Y

2 Years2Y

5 Years5Y

MaxMax

About

Abbott Laboratories engages in the discovery, development, manufacture, and sale of a broad and diversified line of health care products. It operates through the following segments: Established Pharmaceutical Products, Nutritional Products, Diagnostic Products, Cardiovascular and Neuromodulation Products, and Other. The Established Pharmaceutical Products segment refers to the international sales of a line of branded generic pharmaceutical products. The Nutritional Products segment caters to the worldwide sales of adult and pediatric nutritional products. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, and alternate-care testing sites. The Vascular Products segment trades coronary, endovascular, structural heart, vessel closure, and other medical device products. The Other segment comprises of Abbott Medical Optics. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.

CEO

Miles D. White

Employees

107000

Headquarters

100 Abbott Park Road Abbott Park, IL, 60064-6400

Founded

1888

Market Cap

Abbott Laboratories News

COVID-19 diagnostics sales boost Abbott’s Q2 results Jul 16, 2020

Abbott (NYSE:ABT) beat the consensus forecast on Wall Street today — with sales of molecular diagnostics including COVID-19 tests more than tripling. The Abbott Park, Ill.-based healthcare giant reported profits of $537 million or 57¢ per share, on sales of $7.33 billion for the three months ended June 30, 2020, for a bottom-line plunge of –47% […]

ESC Congress 2019: Biotronik beats Abbott at target lesion failure Sep 03, 2019

Biotronik said yesterday that its Orsiro stent tops the Xience stents made by Abbott (NYSE:ABT) when it comes to target lesion failure, according to data from a clinical trial. The randomized, controlled BioSTEMI trial was the first direct comparison between the two drug-eluting stents in patients with acute ST-segment elevation myocardial infarction (STEMI). Biotronik announced […]

Study: Vital Organs Support Systems and Medical Bionics Market to Reach $59.41 Billion by 2025 Jun 07, 2019

Allied Market Research published a report, titled, “Vital Organs Support Systems and Medical Bionics Market by Product (Vital organs support systems and Medical Bionics) and End User (Hospitals, Ambulatory Surgical Centers, and Others): Global Opportunity Analysis and Industry Forecast, 2018–2025.” The report offers a detailed analysis of top investment pockets, top winning strategies, drivers & opportunities, market size…

Judge: Ex-Abbott worker can’t sue twice May 10, 2019

A federal judge in Massachusetts yesterday shot down a second lawsuit brought against Abbott (NYSE:ABT) by a former medical liaison over her claim that the company fired her after she blew the whistle on off-label and pre-approval stent promotion. Ebonia Elliott-Lewis, formerly a regional science manager for Abbott Vascular based in Boston, first sued the company […]

Abbott misses Wall Street expectations on Q4 sales Jan 23, 2019

Abbott (NYSE:ABT) stock is down about 2% today after its fourth-quarter sales failed to meet analyst expectations. The Abbott Park, Ill.–based maker of medical device, pharmaceutical, nutrition and diagnostics products brought in about $7.765 billion in revenue in the quarter ended Dec. 31, 2018. The sales were up 2.3% from $7.589 billion earned during the same […]